Abstract: The present invention is directed to a kit and a method for determining the suitability of a subject to a treatment using a tumor necrosis factor alpha (TNF?). Further provided is a method for treating the subject determined to be suitable for a treatment using a TNF? inhibitor.

Abstract: A method of analyzing the therapeutic efficacy of a therapeutic agent for treating an immune-related disorder is disclosed. The method comprises contacting blood cells of the subject with the agent, measuring the expression of at least 20 genes in the blood cells of the subject; obtaining an immune age value based on the expression of the at least 20 genes, and comparing the immune age value with an immune age value of the subject calculated on the basis of expression of the at least 20 genes in blood cells of the subject, in the absence of the agent.

Abstract: Disclosed is a device including at least 4 sections with a unique layout which includes a surface functionalized with an agent having specific binding affinity to a target molecule, and which allows lateral flow. Disclosed are also a kit and a method for determining and quantifying the presence of an analyte in a sample.

Abstract: Methods of determining suitability of a subject to treatment with an agent that reduces localized inflammation and for converting an unsuitable subject to a suitable one are provided. Kits comprising molecules for doing same are also provided.

Abstract: The invention relates to assays, devices and kits for accurate determination of neutralizing antibodies levels in samples of a subject suffering from an immune-mediated disorder, treated with biological drugs, and for predicting responsiveness to the drug in these patients.

Abstract: The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The pharmaceutical compositions comprise as active ingredient a therapeutically effective amount of a compound which inhibits the growth-enhancing effect of gastrin on H. pylori. The active ingredient may specifically be a compound which is capable of inhibiting gastrin uptake by H. pylori, and/or which is an antagonist of the human or H. pylori gastrin receptor.

Abstract: The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H. pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated with Helicobacter sp infections.

Abstract: The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The pharmaceutical compositions comprise as active ingredient a therapeutically effective amount of a compound which inhibits the growth-enhancing effect of gastrin on H. pylori. The active ingredient may specifically be a compound which is capable of inhibiting gastrin uptake by H. pylori, and/or which is an antagonist of the human or H. pylori gastrin receptor.

Abstract: The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The pharmaceutical compositions comprise as active ingredient a therapeutically effective amount of a compound which inhibits the growth-enhancing effect of gastrin on H. pylori. The active ingredient may specifically be a compound which is capable of inhibiting gastrin uptake by H. pylori, and/or which is an antagonist of the human or H. pylori gastrin receptor.